UNSPSC 51313218: Levocabastine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C26H29FN2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 124XMA6YEI, chemically known as 4-piperidinecarboxylic acid, 1-(cis-4-cyano-4-(4-fluorophenyl)cyclohexyl)-3-methyl-4-phenyl-, monohydrochloride, (3s,4r)- but more generally known as levocabastine hydrochloride, which bears US NIH Compound Identifier 54384.

UNSPSC 51313218 Levocabastine hydrochloride is a Commodity code that in practice covers state and local procurement of pharmaceutical products and allied health supplies, though the recent solicitations show little activity directly matching levocabastine itself. State and local issuers soliciting under related pharmaceutical codes include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The work spans generic multi-source pharmaceuticals, over-the-counter products, and emergency medical countermeasures such as naloxone, all destined for community health buildings, public health systems, and state agency distribution networks. Vendors must meet FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act requirements, and standard insurance minimums including commercial general liability and workers' compensation. Issuing bodies typically require demonstrated wholesaler relationships, electronic data interchange capability, and pricing transparency through fixed or net-pricing models.

The code sees activity across multiple states, with recent solicitations originating in Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (No. IFB60459723LAS) in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring quarterly deliveries to its community health building in Sanford. The Texas Health and Human Services Commission posted an RFI (No. HHS0017013) in April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program serving state agencies and self-insured health plans. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (No. S1070000015802) in January 2026 for generic pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with a proposal deadline of March 26, 2026 and contract effectiveness of July 1, 2026. Price competitiveness weighted at 75 percent of MMCAP's evaluation criteria, with vendors obligated to maintain relationships with authorized wholesalers and pay a 3 percent administrative fee on all contract purchases.